Skin Cancers Completed Phase 2 Trials for Aldesleukin (DB00041)

Also known as: Cancer of Skin / Skin Cancer / [X]Malignant neoplasm of skin, unspecified / Skin malignant neoplasm NOS / Malignant skin neoplasm NOS / Skin neoplasms malignant and unspecified / Skin neoplasm malignant NOS / Skin neoplasm malignant

IndicationStatusPhase
DBCOND0046599 (Skin Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00509288Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered LymphocytesTreatment
NCT00665470Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat MelanomaTreatment
NCT00923195Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic MelanomaTreatment
NCT01118091Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...Treatment
NCT01369875Modified Tumor Infiltrating Lymphocytes for Metastatic MelanomaTreatment